ChromaCode, Inc.

ChromaCode, Inc. has raised $3.8M in total funding. The most recent round was Series C.

ChromaCode, Inc. is headquartered in Carlsbad, CA.

ChromaCode is a leading provider of HDPCR™ multiplexing technology for genomic solutions. Our breakthrough platform enables labs, physicians, and patients to access actionable biomarkers faster and more affordably. With HDPCR™, you can get critical and complete data, analyzed with simplicity, without paying for excess information.

Physicians and lab partners need faster, more cost-effective access to critical genomic biomarkers to guide oncology and disease-management decisions than conventional testing methods allow.

ChromaCode's HDPCR multiplexing platform pairs proprietary chemistry with cloud-based software (ChromaCode Cloud) to deliver multi-analyte genomic assays via reagent kits with automated interpretation, requiring no hardware or software install.

The page cites specific performance claims versus conventional digital PCR: over 4X the multiplexing, under-24-hour turnaround, zero on-site hardware/software installation, and ≥80% margins for lab partners due to lower cost of goods and higher throughput; it also claims broad regulatory compliance (HIPAA, HITRUST, ISO 13485, GDPR).

Carlsbad-based molecular diagnostics company founded in 2012 by Alex Dickinson, Aditya Rajgopal and Greg Gosch; has raised roughly $50M including a Series C from Adjuvant Capital and existing investor Northpond Ventures.